JAK2 and myeloproliferative neoplasm: The discovery of the JAK2-V617F mutation in MPN has led to the development and approval of a JAK1/2 inhibitor, ruxolitinib for the treatment of PMF patients with splenomegaly and constitutional symptoms16.